---
title: "YD Bio Limited (YDES.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/YDES.US.md"
symbol: "YDES.US"
name: "YD Bio Limited"
industry: "Biotechnology"
datetime: "2026-06-19T12:19:07.851Z"
locales:
  - [en](https://longbridge.com/en/quote/YDES.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/YDES.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/YDES.US.md)
---

# YD Bio Limited (YDES.US)

## Company Overview

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ydesgroup.com](https://www.ydesgroup.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-19T04:30:12.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 138 / 389 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.76% |  |
| Net Profit YoY | -10509.73% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 170661688.78 |  |
| Revenue | 510360.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.69% | E |
| Profit Margin | -276.58% | E |
| Gross Margin | 30.44% | C |
| Revenue YoY | 45.76% | A |
| Net Profit YoY | -10509.73% | E |
| Total Assets YoY | 2036.98% | A |
| Net Assets YoY | 28560.72% | A |
| Cash Flow Margin | 130.13% | B |
| OCF YoY | 45.76% | A |
| Turnover | 0.14 | D |
| Gearing Ratio | 3.99% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - YD Bio Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "45.76%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-10509.73%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "170661688.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "510360.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.69%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-276.58%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "30.44%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "45.76%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10509.73%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "2036.98%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "28560.72%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "130.13%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "45.76%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.14",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.99%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -259.26 | 553/389 | - | - | - |
| PB | 55.53 | 434/389 | 138.29 | 107.98 | 56.82 |
| PS (TTM) | 717.07 | 298/389 | 1785.69 | 1394.38 | 733.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/YDES.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/YDES.US/norm.md)
- [Related News](https://longbridge.com/en/quote/YDES.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/YDES.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**